Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Conference Call February 29, 2024 8:00 AM ET Company Participants Mark Marmur - Vice President, Global Corporate Communications Patrick Holt - President and Chief Executive Officer Tom Reilly - Executive Vice President, Chief Financial Officer and Head of Global HR & Finance Conference Call Participants Roanna Ruiz - Leerink Partners Operator Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2023 Financial Result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-21392 | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------|-------------- ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A. The conference call with management will follow the release of the Company's fourth quar ...

It has been a rather lukewarm earnings season for the drug and biotech sector. Majority of large drug/biotech companies reported mixed results and issued fresh guidance for 2024, which was largely optimistic. Several smaller biotechs are scheduled to report earnings results this month.Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.Per the Earnings Trends report, as of Feb 14, 80.0% of the Me ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders: Dear Fellow Amarin Shareholders, 2023 was an important year for Amarin, marked by necessary transition and change. With a new board focused on shareholders, we undertook significant actions to strengthen the Company. We restructured t ...

sasirin pamai/iStock via Getty Images Amarin (NASDAQ:AMRN) isn't dead, after all. Sarissa seems to be doing what they promised to do - turning it around and giving it new life. I wasn't a believer before, but I could well become one soon. Things are looking that good. The Amarin story, very briefly, is this: fish oil has been used for ages as a health supplement. Fish oil contains omega-3 fatty acids, which has been assumed to be responsible for those health benefits. Omega-3 fatty acids are essential p ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amarin (AMRN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Amarin is one of 1077 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of ...

Shares of Amarin Corporation plc (AMRN) surged 32.8% on Jan 10 after the company announced robust preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million.Amarin’s top line currently comprises product revenues from Vascepa/Vazkepa (Vascepa’s brand name in Europe), as well as licensing and royalty revenues.Vascepa (icosapent ethyl) is approved as an adjunct to diet for treating severe hypertriglyceridemia or elevated tri ...

Shares of Amarin (AMRN 32.87%) skyrocketed 32.9% on Wednesday after the biopharmaceutical company announced strong preliminary fiscal fourth-quarter results, a new share-repurchase authorization, and encouraging 2024 guidance.A strong end to Amarin's yearIn a press release this morning, Amarin told investors it now expects fourth-quarter 2023 revenue of between $72 million and $74 million, far above analysts' consensus estimates for sales closer to $62 million. That would bring full-year 2023 revenue to bet ...

Amarin Corporation plc (NASDAQ:AMRN) 42nd Annual J.P. Morgan Healthcare Conference January 10, 2024 4:30 PM ET Company Participants Pat Holt - President & CEO Conference Call Participants Jess Fye - JPMorgan Jess Fye Great. Good afternoon, everyone. Welcome. My name is Jess Fye. I'm a Senior Biotech Analyst at JPMorgan, and we're continuing the 42nd Annual Healthcare Conference today with Amarin. I'm joined up here by the company's President and CEO, Pat Holt. He's going to give a presentation on the busine ...